Comparison of first-line bevacizumab in combination with mFOLFOX6 or XELOX in metastatic colorectal cancer

Bayoglu, Ibrahim; Yildiz, Ibrahim; Varol, Umut; Cokmert, Suna; Kucukzeybek, Yuksel; Alacacioglu, Ahmet; Demir, LÜTFİYE; Dirican, Ahmet; Akyol, Murat; Yildiz, Yasar; Tarhan, Mustafa

Comparison of first-line bevacizumab in combination with mFOLFOX6 or XELOX in metastatic colorectal cancer

Bayoglu I. V., Yildiz I., Varol U., Cokmert S., Kucukzeybek Y., Alacacioglu A., ...More

JOURNAL OF BUON, vol.20, pp.460-467, 2015 (SCI-Expanded, Scopus)

Publication Type: Article / Article
Volume: 20
Publication Date: 2015
Journal Name: JOURNAL OF BUON
Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Page Numbers: pp.460-467
Open Archive Collection: AVESIS Open Access Collection
Eskisehir Osmangazi University Affiliated: No

Abstract

Purpose: Currently, there are several oxaliplatin combination regimens for first-line therapy of metastatic colorectal cancer (mCRC). In this study, we compared the survival outcomes of mCRC patients treated with bevacizumab in combination with either modified 5-FU/FA/oxaliplatin (rnFOLFOX6) or capecitabine/oxaliplatin (XELOX).